Navigation Links
DURECT to Participate in Upcoming Healthcare Conferences
Date:8/21/2012

CUPERTINO, Calif., Aug. 21, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. 

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

  • Matt Hogan, Chief Financial Officer, will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5 at 3:15 p.m. Eastern Time.  The conference is being held at the Four Seasons Hotel in Boston.  A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/stifel/healthcare2012/36113426.cfm
  • James E. Brown, President and CEO, will also present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10 at 3:40 p.m. Eastern Time.  The conference is being held at the Waldorf Astoria in New York.  A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rrshq22/drrx.  

A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceuticalcompany developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR, SABER, ORADUR®, TRANSDUR®, ELADUR and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
2. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
3. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
4. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
5. Hill-Rom to Participate in the Deutsche Bank Securities Health Care Conference
6. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
7. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
8. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
9. BlackStratus participates in Joint FDA-ISPE CGMP Conference
10. ViroPharma To Participate In The JMP Securities Healthcare Conference
11. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
Breaking Medicine News(10 mins):